WO2005030933A3 - Proteine morphogenetique osseuse 7 (bmp-7) utilisee dans le diagnostic et le traitement du cancer - Google Patents

Proteine morphogenetique osseuse 7 (bmp-7) utilisee dans le diagnostic et le traitement du cancer Download PDF

Info

Publication number
WO2005030933A3
WO2005030933A3 PCT/US2004/031468 US2004031468W WO2005030933A3 WO 2005030933 A3 WO2005030933 A3 WO 2005030933A3 US 2004031468 W US2004031468 W US 2004031468W WO 2005030933 A3 WO2005030933 A3 WO 2005030933A3
Authority
WO
WIPO (PCT)
Prior art keywords
bmp
cancer
bone morphogenetic
morphogenetic protein
treatment
Prior art date
Application number
PCT/US2004/031468
Other languages
English (en)
Other versions
WO2005030933A2 (fr
Inventor
Marco G Cecchini
Der Pluijm Gabriel Van
Slobodan Vukicevic
Clemens W G M Lowik
Original Assignee
Genera Doo
Univ Leiden Medical Ct
Univ Bern
Marco G Cecchini
Der Pluijm Gabriel Van
Slobodan Vukicevic
Clemens W G M Lowik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genera Doo, Univ Leiden Medical Ct, Univ Bern, Marco G Cecchini, Der Pluijm Gabriel Van, Slobodan Vukicevic, Clemens W G M Lowik filed Critical Genera Doo
Publication of WO2005030933A2 publication Critical patent/WO2005030933A2/fr
Publication of WO2005030933A3 publication Critical patent/WO2005030933A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des méthodes de diagnostic et de traitement du cancer basées sur la propriété de la protéine morphogénétique 7 (BMP-7) permettant d'inhiber ou d'inverser la progression d'une cellule cancéreuse vers un état plus malin.
PCT/US2004/031468 2003-09-24 2004-09-24 Proteine morphogenetique osseuse 7 (bmp-7) utilisee dans le diagnostic et le traitement du cancer WO2005030933A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50555203P 2003-09-24 2003-09-24
US60/505,552 2003-09-24

Publications (2)

Publication Number Publication Date
WO2005030933A2 WO2005030933A2 (fr) 2005-04-07
WO2005030933A3 true WO2005030933A3 (fr) 2006-05-26

Family

ID=34393035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/031468 WO2005030933A2 (fr) 2003-09-24 2004-09-24 Proteine morphogenetique osseuse 7 (bmp-7) utilisee dans le diagnostic et le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2005030933A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311298A1 (en) 2015-08-25 2018-02-08 Histide Ag Compounds for inducing tissue formation and uses thereof
HUE057153T2 (hu) * 2015-09-17 2022-04-28 Histide Ag Neoplasztikus sejt nem neoplasztikus sejtté alakításához használt gyógyszerészeti együttes, mely egy növekedésifaktor-receptor agonistából és egy adhéziós fehérjeinhibitorból áll, és ezek felhasználása
PL3349776T3 (pl) * 2015-09-17 2021-08-02 Histide Ag Związek farmaceutyczny agonisty receptora czynnika wzrostu i inhibitora białka adhezyjnego do przekształcania komórki nowotworowej w komórkę nienowotworową i jego zastosowanie
WO2017046226A2 (fr) * 2015-09-17 2017-03-23 Histide Ag Association pharmaceutique pour convertir une cellule néoplasique en cellule non-néoplasique et ses utilisations
MX2020009922A (es) * 2018-03-26 2020-10-14 Icahn School Med Mount Sinai Metodos de tratamiento del cancer residual minimo.

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDREWS P.W. ET AL: "Inhibition of proliferation and Induction of differentiation of Pluripotent Human Embryonal carcinoma Cells by Osteogenic Protein-1 (Or Bone Morphogenetic protein-7)", LAB. INVEST., vol. 71, no. 2, 1994, pages 243 - 251, XP000929102 *
CARICASOLE A. ET AL: "Bone Morphogenetic Proteins (BMPs) induce epithelial differentiation of NT2D1 human embryonal carcinoma cells", INT.J.DEV.BIOL., vol. 44, 2000, pages 443 - 450, XP002998558 *
FRANZEN A. ET AL: "BMP-7 Induced Cell Cycle Arrest of Anaplastic Thyroid Carcinoma Cells via p21 and p27", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 285, 2001, pages 773 - 781, XP002998557 *
SCHWALBE M. ET AL: "Differential expression and regulation of bone morphogenetic protein 7 in breast cancer", INT. J. ONCOL., vol. 23, 2003, pages 89 - 95, XP002998555 *
SULZBACHER I. ET AL: "The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter", J. CLIN. PATHOL., vol. 55, 2002, pages 381 - 385, XP002998556 *

Also Published As

Publication number Publication date
WO2005030933A2 (fr) 2005-04-07

Similar Documents

Publication Publication Date Title
EP1333094A3 (fr) Sous-unité catalytique de la télomérase humaine
AU2002243495A1 (en) Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
WO2003055443A3 (fr) Proteines morphogeniques osseuses (bmp), recepteurs desdites proteines et proteines de liaison de ces proteines, et leur utilisation pour le diagnostic et le traitement du glaucome
WO2006089233A3 (fr) Methodes et systemes de diagnostic, de pronostic et de selection du traitement d'une leucemie
AU2003225093A1 (en) Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
WO2005055808A3 (fr) Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
AU2003900747A0 (en) Diagnosis and treatment of pancreatic cancer
MXPA04001524A (es) 29-enoles de rapamicina.
WO2003008583A3 (fr) Nouvelles compositions et methodes relatives au cancer
WO2003101401A3 (fr) Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas
DE60125734D1 (en) Neue aryl fructose-1,6-bisphosphatase inhibitoren
AU2003233451A1 (en) Targets, methods, and reagents for diagnosis and treatment of schizophrenia
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
EP1900827A3 (fr) Procédés et compositions pour la prédiction, le diagnostic, le pronostic et la prévention et le traitement de néoplasies malignes
WO2005000087A3 (fr) Produits genetiques exprimes de facon differentielle dans des cellules cancereuses du colon et leurs methodes d'utilisation ii
WO2003045230A3 (fr) Compositions et procedes contre le cancer
AU2002219137A1 (en) Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer
WO2005030933A3 (fr) Proteine morphogenetique osseuse 7 (bmp-7) utilisee dans le diagnostic et le traitement du cancer
WO2004047757A3 (fr) Diagnostic et traitement des cancers hematopoietiques
WO2004026120A3 (fr) Procedes pour diagnostiquer et traiter des tumeurs, et pour supprimer des promoteurs de cd
WO2003035837A3 (fr) Nouvelles compositions et procedes relatifs au cancer
WO2003071933A3 (fr) Nouvelles compositions et procedes de traitement du cancer
WO2003002765A3 (fr) Cancer
WO2000071081A3 (fr) Methodes de diagnostic et de traitement de la maladie de meniere
AU2003294272A1 (en) Methods for diagnosing the presence or stage of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase